Published in J Exp Clin Cancer Res on July 01, 2010
Identification of novel anti-inflammatory agents from Ayurvedic medicine for prevention of chronic diseases: "reverse pharmacology" and "bedside to bench" approach. Curr Drug Targets (2011) 1.53
Inhibition of NF-kappa B activity in mammary epithelium increases tumor latency and decreases tumor burden. Oncogene (2010) 1.09
Antineoplastic and apoptotic potential of traditional medicines thymoquinone and diosgenin in squamous cell carcinoma. PLoS One (2012) 1.04
Depletion of HDAC6 enhances cisplatin-induced DNA damage and apoptosis in non-small cell lung cancer cells. PLoS One (2012) 0.97
Inauhzin sensitizes p53-dependent cytotoxicity and tumor suppression of chemotherapeutic agents. Neoplasia (2013) 0.96
Antitumor activity of monoterpenes found in essential oils. ScientificWorldJournal (2014) 0.94
Protective effect of thymoquinone against cisplatin-induced ototoxicity. Eur Arch Otorhinolaryngol (2012) 0.90
Thymoquinone inhibits tumor growth and induces apoptosis in a breast cancer xenograft mouse model: the role of p38 MAPK and ROS. PLoS One (2013) 0.90
Thymoquinone reduces migration and invasion of human glioblastoma cells associated with FAK, MMP-2 and MMP-9 down-regulation. Invest New Drugs (2011) 0.84
Thymoquinone induces cell death in human squamous carcinoma cells via caspase activation-dependent apoptosis and LC3-II activation-dependent autophagy. PLoS One (2014) 0.84
Thymoquinone Pretreatment Overcomes the Insensitivity and Potentiates the Antitumor Effect of Gemcitabine Through Abrogation of Notch1, PI3K/Akt/mTOR Regulated Signaling Pathways in Pancreatic Cancer. Dig Dis Sci (2014) 0.83
Cardio-protective and anti-cancer therapeutic potential of Nigella sativa. Iran J Basic Med Sci (2014) 0.81
Thymoquinone-induced conformational changes of PAK1 interrupt prosurvival MEK-ERK signaling in colorectal cancer. Mol Cancer (2014) 0.80
Antagonism between curcumin and the topoisomerase II inhibitor etoposide: a study of DNA damage, cell cycle regulation and death pathways. Cancer Biol Ther (2012) 0.80
Anti-neoplastic agent thymoquinone induces degradation of α and β tubulin proteins in human cancer cells without affecting their level in normal human fibroblasts. Invest New Drugs (2011) 0.80
Cellular responses with thymoquinone treatment in human breast cancer cell line MCF-7. Pharmacognosy Res (2013) 0.80
Combined anticancer activity of osthole and cisplatin in NCI-H460 lung cancer cells in vitro. Exp Ther Med (2013) 0.79
Combinatorial Effects of Thymoquinone on the Anticancer Activity and Hepatotoxicity of the Prodrug CB 1954. Sci Pharm (2013) 0.79
Spices for Prevention and Treatment of Cancers. Nutrients (2016) 0.78
Nigella sativa and its active constituent thymoquinone in oral health. Saudi Med J (2016) 0.77
Anticancer activity of Nigella sativa (black seed) and its relationship with the thermal processing and quinone composition of the seed. Drug Des Devel Ther (2015) 0.77
TQ inhibits hepatocellular carcinoma growth in vitro and in vivo via repression of Notch signaling. Oncotarget (2015) 0.77
Primary human monocyte differentiation regulated by Nigella sativa pressed oil. Lipids Health Dis (2011) 0.75
WW domain binding protein 5 induces multidrug resistance of small cell lung cancer under the regulation of miR-335 through the Hippo pathway. Br J Cancer (2016) 0.75
Anticancer Chemodiversity of Ranunculaceae Medicinal Plants: Molecular Mechanisms and Functions. Curr Genomics (2017) 0.75
Thymoquinone Inhibits Escherichia coli ATP Synthase and Cell Growth. PLoS One (2015) 0.75
Thymoquinone Modulates Blood Coagulation in Vitro via Its Effects on Inflammatory and Coagulation Pathways. Int J Mol Sci (2016) 0.75
Thymoquinone chemosensitizes colon cancer cells through inhibition of NF-κB. Oncol Lett (2016) 0.75
Cytotoxicity of thymoquinone alone or in combination with cisplatin (CDDP) against oral squamous cell carcinoma in vitro. Sci Rep (2017) 0.75
Thymoquinone, as an anticancer molecule: from basic research to clinical investigation. Oncotarget (2017) 0.75
Effect of thymoquinone on head and neck squamous cell carcinoma cells in vitro: Synergism with radiation. Oncol Lett (2017) 0.75
Oral thymoquinone administration ameliorates: the effect of cisplatin on brush border membrane enzymes, energy metabolism, and redox status in rat kidney. Naunyn Schmiedebergs Arch Pharmacol (2017) 0.75
Thymoquinone as a Potential Adjuvant Therapy for Cancer Treatment: Evidence from Preclinical Studies. Front Pharmacol (2017) 0.75
Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature (1970) 1528.65
Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications. Proc Natl Acad Sci U S A (1979) 365.71
Cancer statistics, 2008. CA Cancer J Clin (2008) 86.74
Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med (2006) 34.52
Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med (2005) 31.48
Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med (2002) 24.87
Lung cancer. N Engl J Med (2008) 13.49
NF-kappaB in cancer: from innocent bystander to major culprit. Nat Rev Cancer (2002) 11.39
Cellular processing of platinum anticancer drugs. Nat Rev Drug Discov (2005) 9.47
Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group. J Clin Oncol (2008) 7.35
Targeting polo-like kinase 1 for cancer therapy. Nat Rev Cancer (2006) 4.99
The functional role of the ELR motif in CXC chemokine-mediated angiogenesis. J Biol Chem (1995) 4.77
Epithelial-neutrophil activating peptide (ENA-78) is an important angiogenic factor in non-small cell lung cancer. J Clin Invest (1998) 2.42
Inhibition of polo-like kinase 1 by blocking polo-box domain-dependent protein-protein interactions. Chem Biol (2008) 2.37
In vivo imaging of NF-kappa B activity. J Immunol (2002) 2.36
Prognostic significance of polo-like kinase (PLK) expression in non-small cell lung cancer. Oncogene (1997) 2.25
Thymoquinone: a promising anti-cancer drug from natural sources. Int J Biochem Cell Biol (2005) 1.67
Targeting nuclear factor-kappa B activation pathway by thymoquinone: role in suppression of antiapoptotic gene products and enhancement of apoptosis. Mol Cancer Res (2008) 1.58
Thymoquinone inhibits tumor angiogenesis and tumor growth through suppressing AKT and extracellular signal-regulated kinase signaling pathways. Mol Cancer Ther (2008) 1.55
From here to eternity - the secret of Pharaohs: Therapeutic potential of black cumin seeds and beyond. Cancer Ther (2008) 1.43
Antitumor activity of gemcitabine and oxaliplatin is augmented by thymoquinone in pancreatic cancer. Cancer Res (2009) 1.35
Thymoquinone ameliorates the nephrotoxicity induced by cisplatin in rodents and potentiates its antitumor activity. Can J Physiol Pharmacol (1997) 1.24
Naturally occurring coumarins inhibit human cytochromes P450 and block benzo[a]pyrene and 7,12-dimethylbenz[a]anthracene DNA adduct formation in MCF-7 cells. Chem Res Toxicol (2003) 1.23
TC21 mediates transformation and cell survival via activation of phosphatidylinositol 3-kinase/Akt and NF-kappaB signaling pathway. Oncogene (2002) 1.09
Cisplatin versus cisplatin plus etoposide in the treatment of advanced non-small-cell lung cancer. Lung Cancer Working Party, Belgium. J Clin Oncol (1989) 0.98
Structure-activity studies on therapeutic potential of Thymoquinone analogs in pancreatic cancer. Pharm Res (2010) 0.96
Health literacy and cancer communication. CA Cancer J Clin (2002) 4.66
IGF-I and breast cancer: a meta-analysis. Int J Cancer (2004) 2.03
Is percutaneous nephrolithotomy in solitary kidneys safe? Urology (2013) 1.55
Percutaneous nephrolithotomy in England: practice and outcomes described in the Hospital Episode Statistics database. BJU Int (2013) 1.53
Preventing familial amyotrophic lateral sclerosis: is a clinical trial feasible? J Neurol Sci (2006) 1.51
Hepcidin regulation of ferroportin 1 expression in the liver and intestine of the rat. Am J Physiol Gastrointest Liver Physiol (2003) 1.43
Defining the learning curve for percutaneous nephrolithotomy. J Endourol (2005) 1.42
Mammalian target of rapamycin inhibitors as possible adjuvant therapy for microscopic residual disease in head and neck squamous cell cancer. Cancer Res (2007) 1.38
Decreased hospital length of stay associated with presentation of cases at morning report with librarian support. J Med Libr Assoc (2007) 1.38
Incidental renal stones in potential live kidney donors: prevalence, assessment and donation, including role of ex vivo ureteroscopy. BJU Int (2012) 1.32
Overexpressed eIF4E is functionally active in surgical margins of head and neck cancer patients via activation of the Akt/mammalian target of rapamycin pathway. Clin Cancer Res (2004) 1.31
Applications of loop-mediated isothermal DNA amplification. Appl Biochem Biotechnol (2010) 1.27
Intraspinal stem cell transplantation in amyotrophic lateral sclerosis: a phase I safety trial, technical note, and lumbar safety outcomes. Neurosurgery (2012) 1.27
Advance lung cancer inflammation index (ALI) at diagnosis is a prognostic marker in patients with metastatic non-small cell lung cancer (NSCLC): a retrospective review. BMC Cancer (2013) 1.26
Design and initial results of a multi-phase randomized trial of ceftriaxone in amyotrophic lateral sclerosis. PLoS One (2013) 1.19
Primary plasma cell leukemia: report of 17 new cases treated with autologous or allogeneic stem-cell transplantation and review of the literature. Am J Hematol (2005) 1.16
High chemokine receptor CXCR4 level in triple negative breast cancer specimens predicts poor clinical outcome. J Surg Res (2008) 1.15
Molecular analysis of surgical margins in head and neck squamous cell carcinoma patients. Laryngoscope (2002) 1.15
Novel one-step route for synthesizing CdS/polystyrene nanocomposite hollow spheres. Langmuir (2004) 1.10
Comparison of radiosensitizing effects of the mammalian target of rapamycin inhibitor CCI-779 to cisplatin in experimental models of head and neck squamous cell carcinoma. Mol Cancer Ther (2009) 1.10
Protandim, a fundamentally new antioxidant approach in chemoprevention using mouse two-stage skin carcinogenesis as a model. PLoS One (2009) 1.07
RUNX1 (AML-1) and RUNX2 (AML-3) cooperate with prostate-derived Ets factor to activate transcription from the PSA upstream regulatory region. J Cell Biochem (2006) 1.07
Temporal genomewide expression profiling of DSS colitis reveals novel inflammatory and angiogenesis genes similar to ulcerative colitis. Physiol Genomics (2010) 1.06
Iron Imports. V. Transport of iron through the intestinal epithelium. Am J Physiol Gastrointest Liver Physiol (2006) 1.06
Two clustered 8-oxo-7,8-dihydroguanine (8-oxodG) lesions increase the point mutation frequency of 8-oxodG, but do not result in double strand breaks or deletions in Escherichia coli. Nucleic Acids Res (2004) 1.05
Intraspinal stem cell transplantation in amyotrophic lateral sclerosis: a phase I trial, cervical microinjection, and final surgical safety outcomes. Neurosurgery (2014) 1.04
Management of adult hydrocephalus with ventriculoperitoneal shunts: long-term single-institution experience. Neurosurgery (2011) 1.04
Multimodal management of urolithiasis in renal transplantation. BJU Int (2005) 1.03
Plasma sex steroid hormones and breast cancer risk in Chinese women. Int J Cancer (2003) 1.03
HGF/c-met/Stat3 signaling during skin tumor cell invasion: indications for a positive feedback loop. BMC Cancer (2011) 1.00
Cisplatin-gemcitabine therapy in metastatic breast cancer: Improved outcome in triple negative breast cancer patients compared to non-triple negative patients. Breast (2010) 1.00
YGR198w (YPP1) targets A30P alpha-synuclein to the vacuole for degradation. J Cell Biol (2007) 1.00
Race/Ethnicity has no effect on outcome for breast cancer patients treated at an academic center with a public hospital. Cancer Epidemiol Biomarkers Prev (2009) 0.99
Case report: percutaneous nephrolithotomy for a stone on a Hem-o-lok clip. J Endourol (2008) 0.98
Tissue microarray analysis of eIF4E and its downstream effector proteins in human breast cancer. J Exp Clin Cancer Res (2009) 0.98
Reduced CSF p-Tau181 to Tau ratio is a biomarker for FTLD-TDP. Neurology (2013) 0.95
Roadmap and standard operating procedures for biobanking and discovery of neurochemical markers in ALS. Amyotroph Lateral Scler (2012) 0.95
Operative versus nonoperative management of acute odontoid Type II fractures: a meta-analysis. J Neurosurg Spine (2009) 0.95
Trogocytosis of MHC-I/peptide complexes derived from tumors and infected cells enhances dendritic cell cross-priming and promotes adaptive T cell responses. PLoS One (2008) 0.95
Survival in relation to radiotherapeutic modality for brain metastasis: whole brain irradiation vs. gamma knife radiosurgery. Am J Clin Oncol (2004) 0.95
Discrepancy between clinical asthma control assessment tools and fractional exhaled nitric oxide. Ann Allergy Asthma Immunol (2008) 0.95
The phenotypic radiation resistance of CD44+/CD24(-or low) breast cancer cells is mediated through the enhanced activation of ATM signaling. PLoS One (2011) 0.94
Iron feeding induces ferroportin 1 and hephaestin migration and interaction in rat duodenal epithelium. Am J Physiol Gastrointest Liver Physiol (2008) 0.94
Interactions between ferroportin and hephaestin in rat enterocytes are reduced after iron ingestion. Gastroenterology (2011) 0.93
Interleukin-6 protects against paclitaxel, cisplatin and vincristine-induced neuropathies without impairing chemotherapeutic activity. Cancer Chemother Pharmacol (2008) 0.93
Ceramide glycosylation by glucosylceramide synthase selectively maintains the properties of breast cancer stem cells. J Biol Chem (2012) 0.92
Three 'Pages' in a chapter of accidents. Nephrol Dial Transplant (2003) 0.92
Aggressive mammary carcinoma progression in Nrf2 knockout mice treated with 7,12-dimethylbenz[a]anthracene. BMC Cancer (2010) 0.90
Down regulation of PSA by C/EBPalpha is associated with loss of AR expression and inhibition of PSA promoter activity in the LNCaP cell line. BMC Cancer (2006) 0.89
Association between blood flow and inflammatory state in a T-cell transfer model of inflammatory bowel disease in mice. Inflamm Bowel Dis (2010) 0.89
Commercial insurance triples chances of breast cancer survival in a public hospital. Breast J (2013) 0.88
Ex vivo generation of regulatory T cells: characterization and therapeutic evaluation in a model of chronic colitis. Methods Mol Biol (2011) 0.88
The transcytosis of divalent metal transporter 1 and apo-transferrin during iron uptake in intestinal epithelium. Am J Physiol Gastrointest Liver Physiol (2002) 0.88
Cytomorphology, ultrastructural, and cytogenetic findings in follicular dendritic cell sarcoma: a case report. Acta Cytol (2010) 0.88
Changing trends in human papillomavirus-associated head and neck squamous cell carcinoma. Ann Diagn Pathol (2011) 0.88
Pharmacological intervention studies using mouse models of the inflammatory bowel diseases: translating preclinical data into new drug therapies. Inflamm Bowel Dis (2011) 0.87
Evaluation of fluorescence in situ hybridization as an ancillary tool to urine cytology in diagnosing urothelial carcinoma. Diagn Cytopathol (2003) 0.87
The diagnostic value of cell block as an adjunct to liquid-based cytology of bronchial washing specimens in the diagnosis and subclassification of pulmonary neoplasms. Cancer Cytopathol (2011) 0.87
American College of Chest Physicians consensus statement on the respiratory health effects of asbestos. Results of a Delphi study. Chest (2009) 0.87
Behavior matters--cognitive predictors of survival in amyotrophic lateral sclerosis. PLoS One (2013) 0.87
Systemic pharmacokinetics and cerebrospinal fluid uptake of intravenous ceftriaxone in patients with amyotrophic lateral sclerosis. J Clin Pharmacol (2014) 0.87
Pharmacodynamic evaluation of temsirolimus in patients with newly diagnosed advanced-stage head and neck squamous cell carcinoma. Head Neck (2010) 0.86
Characterization of the roles of the catalytic domains of Mycobacterium tuberculosis ligase D in Ku-dependent error-prone DNA end joining. Mutagenesis (2010) 0.86
In prostate cancer cells the interaction of C/EBPalpha with Ku70, Ku80, and poly(ADP-ribose) polymerase-1 increases sensitivity to DNA damage. J Biol Chem (2006) 0.86
In prostate cancer C/EBPalpha promotes cell growth by the loss of interactions with CDK2, CDK4, and E2F and by activation of AKT. Prostate (2009) 0.85
DMT1 (IRE) expression in intestinal and erythroid cells is regulated by peripheral benzodiazepine receptor-associated protein 7. Am J Physiol Gastrointest Liver Physiol (2012) 0.85
Effect of health insurance coverage on outcome for heart failure in high-risk patients. J La State Med Soc (2012) 0.85
The chemopreventive effects of Protandim: modulation of p53 mitochondrial translocation and apoptosis during skin carcinogenesis. PLoS One (2010) 0.85
Role of the gut-associated and secondary lymphoid tissue in the induction of chronic colitis. Inflamm Bowel Dis (2010) 0.84
The role of routine immunohistochemistry for Helicobacter pylori in gastric biopsy. Ann Diagn Pathol (2010) 0.84
Relationship between inflammation and tissue hypoxia in a mouse model of chronic colitis. Inflamm Bowel Dis (2010) 0.84
Interleukin-6 mediates the platelet abnormalities and thrombogenesis associated with experimental colitis. Am J Pathol (2013) 0.84
Pro-apoptotic effects of 1'-acetoxychavicol acetate in human breast carcinoma cells. Toxicol Lett (2007) 0.84
Stable expression of C/EBPalpha in prostate cancer cells down-regulates metallothionein and increases zinc-induced toxicity. Prostate (2005) 0.83
Generation and immunogenicity of a recombinant pseudorabies virus expressing cap protein of porcine circovirus type 2. Vet Microbiol (2006) 0.83
Impact of race and ethnicity on outcomes for estrogen receptor-negative breast cancers: experience of an academic center with a charity hospital. J Am Coll Surg (2010) 0.83
Association of core-binding factor β with the malignant phenotype of prostate and ovarian cancer cells. J Cell Physiol (2010) 0.83
A phase 1/2 trial of HQK-1001, an oral fetal globin inducer, in sickle cell disease. Am J Hematol (2012) 0.83
Therapeutic evaluation of ex vivo-generated versus natural regulatory T-cells in a mouse model of chronic gut inflammation. Inflamm Bowel Dis (2013) 0.83
The effect of a clinical medical librarian on in-patient care outcomes. J Med Libr Assoc (2013) 0.82
VEGF₁₆₄ isoform specific regulation of T-cell-dependent experimental colitis in mice. Inflamm Bowel Dis (2010) 0.82
Flexible ureterorenoscopy (URS) for lower pole calculi. BJU Int (2012) 0.82
Obstructive hydrocephalus in adult patients: the Louisiana State University Health Sciences Center-Shreveport experience with ventriculoperitoneal shunts. World Neurosurg (2011) 0.81
Activated 5'flanking region of NANOGP8 in a self-renewal environment is associated with increased sphere formation and tumor growth of prostate cancer cells. Prostate (2013) 0.81
Improving the interpretation of ureteroscopic biopsies: use of Bouin's fixative. BJU Int (2011) 0.81
Priming of immune responses against transporter associated with antigen processing (TAP)-deficient tumours: tumour direct priming. Immunology (2009) 0.81
Comparison of FISH and quantitative RT-PCR for the diagnosis and follow-up of BCR-ABL-positive leukemias. Mol Diagn Ther (2007) 0.81
Temporal genome expression profile analysis during t-cell-mediated colitis: identification of novel targets and pathways. Inflamm Bowel Dis (2011) 0.81
Generalized tetanus despite prior vaccination and a protective level of anti-tetanus antibodies. Am J Med Sci (2010) 0.80
A randomized controlled trial of human versus robotic and telerobotic access to the kidney as the first step in percutaneous nephrolithotomy. Comput Aided Surg (2005) 0.80
Relationship among circulating leukocytes, platelets, and microvascular responses during induction of chronic colitis. Pathophysiology (2011) 0.80
Hypoxia-inducible factor-2α and iron absorptive gene expression in Belgrade rat intestine. Am J Physiol Gastrointest Liver Physiol (2011) 0.80
Anticancer activity of the iron facilitator LS081. J Exp Clin Cancer Res (2011) 0.80
Effects of ATRA combined with citrus and ginger-derived compounds in human SCC xenografts. BMC Cancer (2010) 0.79